Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease [3] - The company's lead drug candidate, oxylanthanum carbonate (OLC), is designed to treat hyperphosphatemia in chronic kidney disease patients on dialysis [3] - OLC has shown positive pivotal trial results reported in June 2024, and a New Drug Application (NDA) is currently under review by the U.S. FDA with a target action date of June 28, 2025 [3] Intellectual Property - OLC is protected by a strong global patent portfolio, including an issued patent on composition of matter with exclusivity until 2031, and potential patent term extension until 2035 after approval [3] - The second asset, UNI-494, is a new chemical entity in clinical development for acute kidney injury, which has successfully completed a Phase 1 trial [3] Upcoming Events - Shalabh Gupta, M.D., CEO of Unicycive, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 2:15 p.m. ET [1] - A live and archived webcast of the presentation will be available on the Unicycive website under the Investors section [2]